New peanut allergy treatment now in clinical trials

May 23, 2017, Monash University
New peanut allergy treatment now in clinical trials
L-R: Dr Sara Prickett, Professor Robyn O’Hehir and Emeritus Professor Jenny Rolland have worked together for years on the peanut allergy research and are co-founders of Aravax P/L. Credit: Monash University

A new peanut allergy treatment developed by Monash researchers is now beginning clinical trials in Melbourne and Adelaide.

Professor Robyn O'Hehir is Professor/Director of the Department of Allergy, Immunology and Respiratory Medicine at Alfred Health and Monash University. Her research team, co-led by Professor Jennifer Rolland, identified the critical components of the allergy therapy now being developed by Aravax, an Australian spinout biotechnology company.

The technology uses carefully selected fragments of peanut proteins to switch off . The product is designed to be safer, more rapid, and more convenient than other approaches currently under development. The Aravax team anticipates that simple, monthly injections will be sufficient to achieve clinical benefit.

Dr Pascal Hickey, CEO of Aravax, said the team wants to help people around the world who suffer from peanut allergy to live stress-free lives without constantly fearing a major health event from accidental consumption.

"Our technology aims to alleviate that stress by reprogramming the immune system to tolerate peanuts. By creating a safe, convenient and fast solution to a very serious problem we believe our product will have a global health impact by transforming the lives of patients and their carers," Dr Hickey said.

Almost two in every hundred Australians suffer from peanut allergy, and currently there is no therapy to reduce the severity of allergic reactions that can occur following accidental consumption. Despite patients attempting to follow a peanut-free diet, every year around 40 per cent of peanut allergic individuals will suffer a serious adverse event from inadvertent exposure, including anaphylaxis which can lead to death.

Traditionally, allergy specialists have treated patients using repeated doses of the -causing substance. Similar approaches are being explored to treat , but the use of preparations containing whole carries a high risk of severe reactions and requires daily dosing for lengthy periods. Aravax's product is different because it does not contain the parts of peanut protein that cause severe allergic reactions, and its once-a-month dosing regimen is a far simpler solution than remembering to take medication every day.

In the first ever trial of its product known as PVX108, Aravax will evaluate the safety and tolerability of single and repeated administration across a wide range of doses to determine an appropriate dosing regimen. This double-blinded and placebo controlled trial commenced dosing on 10 May 2017 with the first group of subjects safely receiving the lowest dose of PVX108. The trial is being conducted at CMAX Clinical Research in Adelaide, and at Nucleus Network in Melbourne.

Professor O'Hehir said the research has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council.

"In 2015, we secured AUD $4.85M from the Medical Research Commercialisation Fund (MCRF) to develop the technology through to initial clinical . What is really exciting about this is not only the opportunity we have to get our therapeutic product up and running to protect the many sufferers, but that Australian is being funded in Australia for development to clinical trial," Professor O'Hehir said.

Explore further: Oral immunotherapy is safe, effective for peanut-allergic preschoolers, study suggests

More information: Peanut allergy sufferers interested in participating in the trials can contact Aravax for further information. www.aravax.com.au/product-development.html

Related Stories

Oral immunotherapy is safe, effective for peanut-allergic preschoolers, study suggests

August 10, 2016
Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. Peanut OIT involves eating ...

Anaphylaxis risk up for siblings of peanut allergic children

June 14, 2016
(HealthDay)—The risk of anaphylaxis is increased upon peanut introduction in siblings of children with peanut allergy, according to a study published online June 13 in Allergy.

Study suggests patch is safe, convenient mode of treatment for peanut allergy

October 26, 2016
A wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to one-year results ...

Video: Why are people allergic to peanuts?

March 22, 2016
For 1 to 2 percent of the global population, eating a peanut butter and jelly sandwich could be potentially fatal. What makes peanut allergies so lethal, and why is the number of peanut-allergy sufferers on the rise?

Expert panel issues clinical guidelines to prevent peanut allergy

January 5, 2017
An expert panel sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, issued clinical guidelines today to aid health care providers in early introduction ...

Recommended for you

A synthetic approach to helping the immune system thwart infections

February 22, 2018
Yale researchers have developed a set of synthetic molecules that may help boost the strength of a key, virus-fighting protein.

Scientists find molecular link between Vitamin A derivative and mouse intestinal health

February 22, 2018
New research shows that all-trans-retinoic acid (atRA), the active form of vitamin A, regulates immune system responses in the mouse intestine by controlling expression of the protein HIC1 in cells known as innate lymphoid ...

Animal study shows how to retrain the immune system to ease food allergies

February 21, 2018
Treating food allergies might be a simple matter of teaching the immune system a new trick, researchers at Duke Health have found.

'Icebreaker' protein opens genome for T cell development, researchers find

February 20, 2018
Almost all cells in the human body have identical DNA sequences, yet there are 200-plus cell types with different sizes, shapes, and chemical compositions. Determining what parts of the genome are read to make protein and ...

Preventive treatment for peanut allergies succeeds in study

February 20, 2018
The first treatment to help prevent serious allergic reactions to peanuts may be on the way. A company said Tuesday that its daily capsules of peanut powder helped children build tolerance in a major study.

Infection site affects how a virus spreads through the body

February 20, 2018
A person is more likely to get infected by HIV through anal intercourse than vaginal, but no one knows quite why. A new study by scientists at the Gladstone Institutes shows that infection sites could affect the immune system's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.